

COVID-19 Funding Opportunities

Please note these opportunities are emerging rapidly. Many have quick turnaround times. Check dates carefully. Also included are supplement opportunities for current NIH grantees working in related areas.

[Military-Related Solicitations](#)

The Medical Technology Enterprise Consortium (MTEC) is seeking proposals focused on the development of COVID-19 treatments with potential application to the prevention of infection and therapeutics that can be administered in a non-hospital environment. Military relevance is a critical component of this solicitation.

[BARDA](#)

The Office of Biomedical Advanced Research & Development Authority (BARDA) is soliciting applications for topics specifically relating to COVID-19, including diagnostic assays, point-of care-diagnostic assays, vaccines, therapeutics, prophylaxis, respiratory protective devices, and ventilators.

[Medical CBRN Defense Consortium \(MCDC\) Other Transaction Agreement \(OTA\) Request for Information \(RFI\) – CoV Pandemic Response](#)

The Government is requesting White Papers with a focus on the following areas:

Diagnostics/Monitoring: Medical diagnostic devices, with specific emphasis on Point-of-Care diagnostics (e.g. CLIA waived), under development and capable of diagnosing 2019- SARS-CoV-2, and achieving Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA) within the next one to four (1-4) months. **Surveillance:** Surveillance methods and associated devices for 2019-SARS-CoV-2 screening. Any technology that can enhance the understanding of disease progression in COVID-19 infected patients is also of interest, including physiologic monitoring and other vital signs indicators, portable technology that enhances patient care in non-hospital settings, and technology that improves sample collection. **Therapeutics:** Drugs and/or drug/device combinations, or platforms currently under development demonstrating efficacy in post-exposure, pre- and post-symptomatic studies for any CoV strain, and capable of achieving EUA from the FDA within the next three months for this ongoing SARS-CoV-2 pandemic. Antibody technologies, accelerating the discovery, development, manufacturing, and prediction of success for these technologies, can also be considered. **Prophylactics:** Drugs or vaccines currently under development demonstrating pre-exposure in vivo efficacy or in vitro activity against any or all strains of CoV. Antibody technology, accelerating the discovery, development, manufacturing and prediction of success for these technologies can be considered. **Clinical Trials:** Opportunities to expeditiously conduct clinical trials for any technology that will require evaluation for FDA approval, will be considered. This RFI is open to the public, offerors are not required to be a MCDC member or have previously been a DoD contractor. All contractors can submit to the RFI regardless of their nontraditional/traditional defense contractor status.

[NSF Letter on COVID-19](#)

NSF is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate

about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.

[NSF Provisioning Advanced Cyberinfrastructure to Further Research on COVID-19](#)

The Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting [RAPID](#) proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities.

[Dear Colleague Letter: Request for SBIR/STTR Phase I Proposals Addressing COVID-19](#)

The Division of Innovation and Industrial Partnerships (IIP) of the Engineering Directorate invites US-based small businesses to submit Phase I proposals focused on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nation's and world's ability to respond to the COVID-19 crisis. Areas of research that might be considered include, but are not limited to: artificial intelligence, digital health, diagnostics, distributed ledger, environmental technologies, medical devices, pharmaceutical technologies, disinfection and sterilization, and filtration and separations. Interested proposers are invited to submit to the NSF Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase I Program.

[COVID-19 HPC Consortium](#)

The COVID-19 High Performance Computing Consortium is a unique private-public effort to bring together federal government, industry, and academic leaders who are volunteering free compute time and resources on their world-class machines. Researchers are invited to submit COVID-19 related research proposals to the consortium, which will then be reviewed for matching with computing resources from one of the partner institutions.

[C19 Artificial Intelligence for Rapid Response Grant](#)

The Grant will help institutions implement a solution that gets constituents rapid responses to FAQs. The Yoda Rapid Response AI-enabled chat service allows for: -FAQs to be addressed 24x7 with Anytime Anywhere Access; -improved student engagement during C19 crisis; -faster responses; -reduces errors and miscommunication by standardizing FAQ repository and resource guides.

Accredited Higher Education institutions and K-12 schools are eligible to apply. Institutions are eligible to apply for multiple grants. Separate applications are required for each grant pursued.

[Partnerships for Countermeasures against Select Pathogens \(R01 Clinical Trials Not Allowed\)](#)

The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.

[Notice of Special Interest \(NOSI\) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 \(COVID-19\) and the Causative Virus SARS-CoV-2](#)

NIGMS will accept the submission of applications for Competitive Revisions to active grants to address only the following research areas of interest:

- Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants).
- Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection (SBIR/STTR grants only).
- Rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR only).

[Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements \(Urgent Supplement - Clinical Trial Optional\)](#)

NIH hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award. Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA. Individual(s) must hold an active grant or cooperative agreement, and the research proposed in the supplement must be accomplished within the competitive segment of the active award. Individuals are encouraged to work with their organizations to develop applications for support

[Notice of Special Interest \(NOSI\) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus](#)

NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders. Applicants should be submitted using one of the two Supplement PAs (PA-18-591, where the work proposed in the supplement is fully within the scope of the ongoing grant; and PA-18-935, for grantees wishing to expand the scope of their active grant)

[Notice of Intent: New Funding Opportunity Announcement to Support Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19](#)

The health systems research community should prepare to submit applications to AHRQ to fund critical research focused on evaluating topics such as innovations and challenges encountered in the rapid expansion of telemedicine in response to COVID-19, effects on quality, safety, and value of health system response to COVID-19, and the role of primary care practices and professionals during the COVID-19 epidemic. AHRQ is particularly interested in understanding how digital health innovations contributed to health system and healthcare professional innovation and challenges and solutions to meeting the needs of vulnerable populations including older adults, people living with multiple chronic conditions, rural communities, and uninsured and underinsured populations.

[Competitive Fund for Peace and Recovery](#)

As COVID-19 spreads around the world, IPA's Peace & Recovery Program is accepting off-cycle proposals, capped at \$50,000, for time-sensitive additions to research projects that study or support the COVID-19 response. Due to the limited funding available, this funding will likely not fund entire randomized evaluations, but is meant to support research projects with additions such as:
Adding a module to an existing survey in order to track COVID-19 exposure or response,
Adding a treatment arm that may support communities' resiliency in response to COVID-19,
Anonymizing, curating, and sharing already-collected data quickly so that it can be used for decision-making by the humanitarian community, or "Downstream surveys" that follow up on a sample that participated in an already-completed randomized trial in order to identify whether the intervention studied has an impact on the communities' response to COVID-19. Interested applicants should first send an email to peace@poverty-action.org asking for more information on how to submit an off-cycle proposal.

[MIT Solve](#)

MIT Solve is seeking tech innovations that can slow and track the spread of an emerging outbreak, for example by improving individual hygiene, developing low-cost rapid diagnostics, analyzing data that informs decision making, and providing tools that support and protect health workers. Solve is also seeking solutions that focus on preventative and mitigation measures that strengthen access to affordable primary healthcare systems, enhance disease surveillance systems, and improve healthcare supply chains. Anyone, anywhere around the world can submit a solution to Solve's Challenges. The applicant can be an individual, a team, or an organization. They can be an applicant from previous years or already part of the community.

[NIST Manufacturing USA National Emergency Assistance Program](#)

NIST invites applications from the 2,000 current Manufacturing USA institute, including small manufacturers, two-thirds of Fortune 50 U.S. manufacturers, and nearly every top ranked research and engineering university in the United States. Projects should focus on responding to the COVID-19 pandemic. Projects may include medical countermeasures; non-medical countermeasures; leveraging institute capabilities to strengthen state and community resilience; grants to companies and technical support to accelerate productions of critical materials, equipment, and supplies; creation of additional production facilities; technology roadmapping for pandemic response and recovery; reshoring the manufacture of critical conventional drugs and ensuring supply chain for critical materials related to pandemic response; or workforce development and training for a skilled advanced manufacturing workforce.

<https://www.grants.gov/web/grants/search-grants.html?keywords=2020-NIST-MFGUSA-NEAP-01>

[The 2020 Call for Code Global Challenge](#)

The Call for Code Global Challenge, an initiative of IBM, asks the world's developers to build solutions for COVID-19 and climate change. Interests include crisis communication, remote education, and community cooperation.